Home › Alexion: 2 Global Drug Rollouts, But Upside Already Priced In
 

Keywords :   


Alexion: 2 Global Drug Rollouts, But Upside Already Priced In

2015-12-06 11:18:40| Biotech - Topix.net

Alexion is highly overvalued, even assuming best case peak sales projections of $1B for Strensiq, $1B for Kanuma, and $5B for Soliris. Payer risk for high-priced drugs isn't going away and orphan drug companies can't expect to keep getting a free pass.

Tags: in global drug priced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Delayed implementation of EID eartag rule requested
More »